Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-551 in Adult Neuromyelitis Optica / NMOSD: Double-masked, Placebo-controlled with Open-label Period
jRCT2080223977Phase 3Recruiting
- Sponsor
- MedImmune
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neuromyelitis optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing MEDI-551 with Placebo (2 arms). Started Jul 2018; status: recruiting.
02
Drugs
inebilizumab
03
Conditions
neuromyelitis optica (NMO)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCT2080223977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223977.